WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pandion Therapeutics, Inc. ("Pandion" or the "Company") (NASDAQ: PAND) in connection with the proposed all-cash acquisition of the Company by Merck Sharp & Dohme Corp. (NYSE: MRK). Under the terms of the merger agreement, Pandion shareholders will receive $60.00 in cash for each share of Pandion common stock that they own. The transaction is valued at approximately $1.85 billion .
If you own PAND shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
1500 Broadway, 16 th Floor
New York , NY 10036
WeissLaw LLP is investigating whether (i) Pandion's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $60.00 per-share merger consideration adequately compensates Pandion's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at firstname.lastname@example.org
View original content to download multimedia: http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-pandion-therapeutics-inc-301235990.html
SOURCE WeissLaw LLP